Study of an investigational drug for advanced prostate cancer
This trial tests a new drug called QLS2401 for patients with advanced prostate cancer that has spread and no longer responds to standard treatments. The goal is to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread to other parts of the body and has stopped responding to hormone therapy and other standard treatments.
- You are generally able to take care of yourself (able to do light activity and be up and about).
- You have recovered from the side effects of your previous cancer treatments.
- You have not had certain types of prior therapy (like PSMA-targeted therapy, T-cell engagers, or recent chemotherapy or other cancer drugs) unless specifically allowed by the study.
- You do not have brain metastases or other serious conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
This trial tests an investigational drug called QLF4113 for men with metastatic castration-resistant prostate cancer (mCRPC) that has not responded to standard treatments. The goal is to see if QLF4113 can help control the cancer.
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests an experimental drug (QLS1209) for advanced solid tumors that have not responded to standard treatments or when no standard treatment exists. The study looks for tumors with certain genetic changes (in CCNE1, FBXW7, or PPP2R1A) and may help guide future treatment options.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.